In, 2016, the FDA approved Atezolizumab as a therapy for patients with metastatic NSCLC who have experienced disease progression during or following platinum-containing chemotherapy, and if their tumor has EGFR or ALK gene abnormalities. This evidence concerns the gene ALK and neoplasm.